Back to search results

Observational Study for Stage II/III Colorectal Cancer Recurrence

This observational study aims to develop a test called CENSURE to predict if colorectal cancer (CRC) will come back in patients who have completed chemotherapy for Stage II or III CRC. CENSURE looks at specific markers in the DNA from your original tumor. You may be eligible if you are 18 or older, have Stage II (high-risk) or Stage III colorectal cancer, and have already had surgery and chemotherapy. The main goal is to see how well CENSURE can predict how long patients remain free from cancer recurrence, with follow-up for up to 10 years. This study is currently in an unclear status regarding recruitment.

Study design
This is an observational study planning to include 400 participants. It will involve three phases to discover, develop, and validate a biomarker panel.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to measure recurrence-free survival for up to 120 months (10 years).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06314958

Stage II/III Colorectal Cancer Recurrence

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~400 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:CENSURE

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recurrence-Free Survival
Measured over Up to 120 months

Conditions

Colorectal Cancer
Colorectal Adenocarcinoma
Colorectal Cancer Stage II
Colorectal Cancer Stage III
Colorectal Cancer Recurrent

Explore related trials

Colorectal Carcinoma

Where it's being run

4 sites across 3 states
Spain2
California1
China1

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ajay Goel, PhD
[email protected]
6262183452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
Confirmed cancer-free survivorship confirmed at the time of study inclusion.

Exclusion

Lack of written informed consent.
Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
Hereditary colorectal cancer syndromes (identified through genetic testing)
Inflammatory bowel diseases

What this trial measures

  • Recurrence-Free SurvivalUp to 120 months

    Time from treatment completion to development of recurrence (or death)